Program Information

  • Phone: 215-525-8695
  • Location: 1233 Locust St, 5th floor, Philadelphia PA 19107

Philadelphia FIGHT (FIGHT) was founded as the Community Based Research Initiative on AIDS as a partnership of individuals living with HIV/AIDS and clinicians who joined together to improve the lives of people living with the disease by testing potential treatments for HIV/AIDS and its complications. Today, clinicians at FIGHT continue to be involved in a number of studies.

What is a clinical trial?

A clinical trial is a controlled experiment in which people take medication for a specified time to determine its effectiveness and safety. Information gathered from clinical trials help create future treatments. Clinical trials are currently the most effective way to help people who have exhausted all proven therapies and to develop new and better treatments for people living with HIV/AIDS.

Who can enroll in a trial?

Each clinical trial has specific requirements; anyone meeting those requirements may be eligible to enroll in a trial. FIGHT clinical trials are free and participation is voluntary. Before participating in a study, patients go through a consenting process, which explains all the risks and benefits of that particular study. Participants may withdraw from clinical trials at any time without affecting access to their health care.

Click the link to view ongoing trials conducted at Philadelphia FIGHT Community Health Centers.

If you are interested in participating in clinical trials, please contact the research staff of Philadelphia FIGHT at 215-525-8695.

What’s new in FIGHT Research?

Congratulations to Dr. Helen Koenig and the PrEP Research Team – Dr. Koenig and the PrEP research team demonstrated that a urine test can be used to monitor adherence to Truvada™ taken as pre-exposure prophylaxis (PrEP) for prevention of HIV. This work was done to address a major research gap as, currently, there is no way to reliably measure adherence to PrEP and help patients taking this medication overcome barriers to adherence. Dr. Koenig and her team were invited to present these results at the Gates Foundation in Seattle, as part of the National Center for AIDS Research (CFAR) Symposium, and awarded the Linden CFAR Award. This award, supported by funds donated to the NIH CFAR Program to advance research in HIV/AIDS, was presented to the three investigators whose work demonstrated great significance, analytical and scientific rigor, novel/innovative methodologies, understandability to a wide scientific audience, and overall contribution to knowledge. The semi-quantitative urine assay using liquid chromatography mass spectrometry that allowed the group to determine tenofovir (TFV) concentrations in log categories between <10 ng/ml to > 10,000 ng/ml and validated this test in HIV positive subjects with undetectable HIV viral loads on a TFV-based regimen,  HIV-negative subjects who received one dose of Truvada™, and 3) HIV-negative subjects receiving daily PrEP . Results demonstrated that urine TFV concentration > 1000 ng/ml was highly predictive of presence of TFV in plasma (>10 ng/ml) (PPV 0.95, 95%CI, 0.80-0.99; NPV 0.79, 95%CI, 0.49-0.94), suggesting that the urine assay could be used to distinguish between recent adherence as defined by a dose of TFV within 48 hours (>1000 ng/ml), low adherence (>10 to >100 ng/ml), and non-adherence as defined by last dose more than one week prior (<10 ng/ml).


November 2015 –  Angela Kapalko, PA-C, Senior Clinical Research Coordinator, and Linden Lalley-Chareczko, MA, Research Coordinator, had the honor of presenting original research at the 2015 American AssociIMG_1871ation for the Study of Liver Diseases (AASLD) Conference in San Francisco, California. A study designed by Angela Kapalko, PA-C and Linden Lalley-Chareczko, MA of the Research department showcased the success of the HIV/HCV co-infection treatment efforts made by the Lax Center from 2011-2014. This was the only community based project focusing solely on co-infection presented at this conference. The data presented reflect the impact made by the patient-centered/integrated care provided at the Lax Center.